Clinical Benefit of High-Sensitivity KRAS Mutation Testing in Metastatic Colorectal Cancer Treated with Anti-EGFR Antibody Therapy

By  

Oncology, Vol. 82, Iss. 5, 2012-04 ,pp. : 298-304

Karger

Access to resources Recommend Favorite

The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway

By  

Oncology, Vol. 77, Iss. 1, 2010-02 ,pp. : 57-68

Karger

Access to resources Recommend Favorite

The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies

By  

Reviews on Recent Clinical Trials, Vol. 9, Iss. 1, 2014-03 ,pp. : 8-12

Bentham Science Publishers

Access to resources Recommend Favorite

Lessons Learned from the Edrecolomab Story: How a Checkered Past Became a Checkered Flag for Monoclonal Antibodies in Colorectal Cancer Therapy

By  

Oncology Research and Treatment, Vol. 28, Iss. 6-7, 2005-06 ,pp. : 311-312

Karger

Access to resources Recommend Favorite

Cancer colorectaux métastatiques et thérapies ciblées anti-EGFR

By Viret Frédéric   Gonçalves Anthony  

Médecine/sciences, Vol. 25, Iss. issue, 2010-12 ,pp. : 13-21

Edp Sciences

Access to resources Recommend Favorite